06855 ASCENTAGE PHARMA GRP INTL

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by the Ascentage management team.

The English conference call and webcast will be held at 8:00 am EDT / 8:00 pm HKT on March 27, 2025. To access the English conference call, please register in advance to obtain a local or toll-free phone number and your personal pin.   A live webcast of the English conference call will be available on the Ascentage Pharma website at: .

Ascentage will host a Chinese (Mandarin) investor event at 9:30 am HKT on Friday, March 28, 2025 (9:30 pm EDT on Thursday, March 27, 2025), which will also be available simultaneously via conference call and webcast.  To access the Chinese investor event or conference call, please register in advance .

The webcast replay for both conference calls will also be available on the page of the Ascentage Pharma website and will be archived for 30 days.

About Ascentage Pharma

Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol “AAPG” since January 2025.

Contacts

Investor Relations

Hogan Wan, Head of IR and Strategy

Ascentage Pharma



7

Stephanie Carrington

ICR Healthcare



(646) 277-1282 

Media Relations

Sean Leous

ICR Healthcare



(646) 866-4012



EN
12/03/2025

Underlying

06855ASCENTAGE PHARMA GRP INTL

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ASCENTAGE PHARMA GRP INTL

 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide ...

Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that it will release its six months 2025 unaudited interim results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on August 20, 2025 / 7:00 am Hong Kong Time (HKT) on August 21, 2025. Analy...

August 7, 2025 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma to Participate in Evercore China Biotech Summit

Ascentage Pharma to Participate in Evercore China Biotech Summit ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that the Company's management will participate in the Evercore China Biotech Summit being held on August 19 - 21, 2025 in Shanghai, China. Management will be participating in a fireside chat moderated by the Evercore ISI Research team and one-on-one i...

August 1, 2025 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conferen...

Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 ROCKVILLE, Md. and SUZHOU, China, July 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced today that the Company's management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested i...

July 23, 2025 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Place...

Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement ROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the closing of an offshore placement (the “Offshore Placement”), pursuant to which Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), offered and sold 22 million ordinary shares,...

July 17, 2025 1 EN
 PRESS RELEASE
Free
06855 ASCENTAGE PHARM...

Ascentage Pharma Announces Pricing of Top-Up Placement

Ascentage Pharma Announces Pricing of Top-Up Placement ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D.,...

July 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch